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PRACTICE POINT
Conformal radiotherapy facilitates the delivery of concurrent
chemotherapy and radiotherapy: a case of primitive neuroectodermal
tumour of the chest wall
C. E. COLES, N.TWYMAN, H. M. EARL & N. G. BURNET
Department of Oncology, Addenbrooke’s Hospital, Cambridge, UK
Abstract
We illustrate the principle of conformal radiotherapy by discussing the case of a patient with a primitive neuroectodermal
tumour of the chest wall. Recent advances in radiotherapy planning enable precise localization of the planning target volume
(PTV) and normal organs at risk of irradiation. Customized blocks are subsequently designed to produce a treatment ®eld
that `conforms’ to the PTV. The use of conformal radiotherapy (CRT) in this case facilitated the delivery of concurrent
chemotherapy and radiotherapy by signi®cantly reducing the volume of red marrow irradiated. The lack of acute and late
toxicities was attributed to optimal exclusion of normal tissues from the treatment ®eld, made possible by CRT.
Key words: primitive neuroectodermal tumour of chest wall, conformal radiotherapy
Introduction
Conformal radiotherapy (CRT) is of proven bene®t in
reducing normal tissue toxicity without jeopardizing
local control in carcinoma of prostate.1 Similar
considerations apply to many other sites since CRT
allows accurate localization of the planning target
volume with sparing of critical structures. Application
of these modern radiotherapy techniques will improve
outcome by reducing normal tissue complications and
may increase local tumour control by allowing dose
escalation. These concepts are also highly relevant in
combined modality treatment using concurrent
chemotherapy and radiotherapy. Advantages of
concomitant treatment are avoidance of delay in both
modalities, and possible greater tumour kill due to the
sensitizing effects of chemoradiation. Disadvantages
include increased radiotherapy side-effects as well as
the effects of overlapping toxicities. An important
example is irradiation of large volumes of bone marrow
causing exacerbation of chemotherapy-induced myelo-
suppression, resulting in treatment delay and thus
possibly compromisingcure.We discuss a case in which
CRT reduced the bone marrow volume irradiated and
thus facilitated concurrent treatment.
Case report
A 20-year-old farmer presented with a 2-week history
of a painful mass on the left posterolateral chest wall.
Closer questioning revealed he had had mild
discomfort in this area for some months. There was
no other relevant history and he was otherwise well.
A computerized tomography (CT) scan of the thorax
showed a 6-cm soft tissue mass surrounding and
destroying the posterolateral left ninth rib. Tumour
extended through the chest wall to involve serratus
anterior and a small left pleural effusion was present.
Biopsy showed small round blue cells in keeping with
a primitive neuroectodermal tumour (PNET), and
this was con®rmed by immunohistochemistry.
He commenced etoposide, vincristine, adriamycin,
ifosfamide and actinomycin D (EVAIA)
chemotherapy with dosages and scheduling as per
the high-risk arm of European Intergroup Coopera-
tive Ewings Sarcoma Study (EICESS) 92 protocol
(Table 1). Following ®ve cycles of chemotherapy,
surgery was undertaken. A central portion of the
eighth rib and the entire ninth rib with the attached
intercostal soft tissue were resected.There were some
¯imsy adhesions to the left lower lobe, but no direct
involvement of the lung or the diaphragm. A single
1.531.0 mm tumour deposit was the only residual
disease identi®ed following chemotherapy. This was
clear of the closest resection margin by 1.5 mm.
Radiotherapy was given at this stage as per the
EICESS 92 protocol. There were no delays, as the
planning and treatment programme was organized in
advance to anticipate the waiting list.The patient was
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positioned in a customized vacuum bag to ensure
reproducible set-up, and his arms were raised above
his head to permit CT scanning.The phase 1 target
volume encompassed the entire left hemithorax
including the tumour, and phase 2 covered the original
tumour site with a margin. Prior chemotherapy and
surgery had removed the gross tumour volume and
therefore the prosthesis was taken to represent the
clinical target volume (CTV) in phase 2. A margin of
1 cm around the CTV was allowed for set-up error
and formed the planning target volume (PTV).
Accurate lung compensation was possible using the
information from the CT scan.
Conformal planning for phase 1 permitted exclu-
sion of the whole of the inferior and superior vertebral
bodies and parts of all the others, thus sparing a
substantial volume of red marrow. Fig. 1 shows the
axial view, regions of interest and beam’s eye view of
the open ®eld arrangement without blocks.The same
views are shown in Fig. 2, but the addition of
conformal blocks illustrates the vertebral shielding.
The humoral head and ipsilateral kidney were also
shielded. Addenbrooke’s radiotherapy planning
system (ARPS) was used to create dose-volume
histograms (DVHs) of the vertebrae both before and
after shielding.Without conformal blocks, the volume
of the spine receiving more than 10% of the tumour
dose (1.95 Gy) was 27.9 mm3; with shielding, this
was reduced by 50% to 13.95 cm3. The DVHs are
shown in Fig. 3. Phase 2 was planned conformally to
limit the volume of lung and ribcage receiving the
higher dose. Movement of the chest wall was screened
in the simulator to ensure adequate coverage of the
target volume throughout respiration. This
demonstrated very little movement at the original
tumour site due to resection and repair with a bone
cement prosthesis.
The patient received a blood transfusion prior to
radiotherapy and his haemoglobin was maintained
above 12 g/dl.This is standard policy in our Sarcoma
Unit as this has been shown to in¯uence oxygenation
and tumour response.2 Phase 1 consisted of 19.5 Gy
lung dose in 13 fractions over 2.5 weeks using parallel
opposed anterior and posterior ®elds. Phase 2
consisted of 36 Gy tumour dose in 20 fractions over
4 weeks using a three-®eld plan. The photon energy
was 8 MV for both phases. During treatment of the
hemithorax, chemotherapy was stopped to avoid
potential pulmonary sensitization leading to lung
damage. Chemotherapy was resumed during phase
2, but adriamycin and actinomycin D were omitted.
Concomitant chemoradiation was well tolerated with
the only side-effect being mild fatigue.
A total of 13 courses of EVAIA chemotherapy were
administered. Radiotherapy was given concurrently
with cycles 9 and 10 of chemotherapy. There was
only one delay due to neutropenic sepsis, which
preceded radiotherapy treatment. Small dose reduc-
tions of 10±20% were made during the last ®ve cycles
due to persisting neutropenia. This intensive
chemotherapy regimen often requires dose reduc-
tions or treatment delays, even in the absence of
concurrent radiotherapy.
Discussion
PNET tumours of the chest wall are uncommon,
but we have experience of two other cases that were
treated in a similar way. All had minimal acute
toxicity and no long-term treatment-related sequelae
to date. Median length of follow-up was 28 months,
with a range of 16±43 months. This suggests that
CRT confers considerable advantage by decreasing
late normal tissue damage with no loss of local
control. In soft tissue sarcomas speci®cally, it has
been shown that advanced radiotherapy planning
can reduce the volume of normal tissue irradiated
by around 30%.3
Chemotherapy dose intensi®cation has been carried
out over the last 10±20 years, and this has led to
increasing acute toxicity, particularly with haemato-
logical and infective complications.4 In the recently
published results from the UK study for axial primary
tumours, the combination of surgery and
radiotherapy, as well as chemotherapy, seemed to be
more effective than surgery alone. There were no
local relapses amongst 11 patients receiving
radiotherapy compared with 12 out of 41 (29%) of
patients relapsing where radiotherapy was not given.
The local control rates in this study were similar to
the Cooperative Ewings Sarcoma Study (CESS) 86
study.4 The concept of reduced toxicity with radia-
tion technique is extremely important, as it is highly
likely that future chemotherapy regimens will include
dose intensi®cation and high-dose treatments. For
example, decreasing the amount of marrow involved
in the radiotherapy ®eld will facilitate the delivery of
planned chemotherapy dose with no additional delays.
The technique of CRT planning involves outlining
Table 1. EVAIA chemotherapy for high-risk patients as per EICESS 92 protocol
Drug Dose (mg/m2) Day Cycle
Etoposide 150 1, 2, 3 3-weekly
Vincristine 1.5 1 3-weekly
Adriamycin 20 1, 2, 3 6-weekly, alternating with actinomycin D
Ifosfamide 2000 1, 2, 3 3-weekly
Actinomycin D 0.5 1, 2, 3 6 weekly, alternating with adriamycin
Mesna 2000 1, 2, 3, 4 3-weekly
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the axial CTV on each CT slice. This can be time-
consuming, given that the superior±inferior CTV
dimensions are often large.We have developed ARPS,
an advanced planning system, with algorithms to
`grow’ the CTV isotropically into the PTV. This
software has reduced clinician-planning time and
greatly assisted veri®cation due high-quality digitally
reconstructed radiographs.
Hemithoracic radiotherapy has not been de®nitely
proven to be necessary in patients with PNET of the
chest wall and pleural effusions. The best data,
however, come from the CESS group.These show an
overall survival of 60% and an event-free survival of
50% at 5 years, using their routine strategy to irradiate
the hemithorax in these patients.5 Quality of
radiotherapy planning has been shown to be important
in patients with Ewing’s tumour. The CESS 81 and
86 studies demonstrated that better planning
conferred an improved outcome; CRT is likely to
extend this advantage.6
Previous studies have addressed the issue of dose
in Ewing’s and PNET tumours. A dose less than
40 Gy is ineffective, but in the dose range of 40±66 Gy
there is little evidence of a dose±response relation-
ship.7 This data set included all tumour sites, and
volume data were not available. Where volume has
been measured prospectively in studies, it has been
shown to be an important prognostic factor.6 In large
tumours, e.g. more than 100 ml,6 it would be expected
that a higher dose would improve local control.This
could be achieved with acceptable acute toxicity using
CRT. Reduction of the volume of normal tissue
treated will also reduce late normal tissue effects and
possibly decrease the incidence of radiation-induced
second malignancies.
The combined approach to this condition, using
chemotherapy, surgery and radiotherapy, is leading
to improvements in local control and survival. In
these circumstances, the issue of late normal tissue
effects becomes all the more important.
We presented this case as an illustration of the
application of standard CRT techniques in patients
with PNET of the chest wall. CRT, within the multi-
disciplinary setting, is of value for these patients, most
of whom are young and with an otherwise long life
expectancy.
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Figure 3. DVH of phase 1 region and vertebral bodies with and without shielding blocks.
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